Outcomes of resectable and borderline resectable pancreatic cancer patients in rural practice.

被引:0
|
作者
Rashad, Sadaf
Bulbul, Ajaz
Jean, Brian
Gholam, Sami
Araujo-Mino, Emilio Paul
Braik, Tareq
Khorsand-Sahbaie, Masoud
机构
[1] All St Univ, Sch Med, Chicago, IL USA
[2] Kymera Independent Phys, Carlsbad, NM USA
[3] Taft Coll, Taft, CA USA
[4] Kern Med Ctr, Bakersfield, CA USA
[5] Univ New Mexico, Albuquerque, NM 87131 USA
[6] Kymera Independent Phys, Roswell, NM USA
关键词
D O I
10.1200/JCO.2017.35.15_suppl.e15712
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
e15712
引用
收藏
页数:5
相关论文
共 50 条
  • [31] The surgical outcomes of borderline resectable or locally advanced pancreatic cancer
    Okamura, Yukiyasu
    Sugiura, Teiichi
    Ito, Takaaki
    Yamamoto, Yusuke
    Ashida, Ryo
    Ohgi, Katsuhisa
    Uesaka, Katsuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [32] Predictive value of exosomes for therapy response in resectable/borderline resectable pancreatic cancer patients
    Cazacu, I. M.
    Croitoru, V. M.
    Paul, D.
    Popa, E.
    Matei, I.
    Gheorghe, C.
    Herlea, V.
    Diculescu, M.
    Bogdan, D.
    Sandra, I.
    Gramaticu, I-M.
    Luca, N. I.
    Dinu, I. M.
    Alexandrescu, S.
    Sorop, A.
    Croitoru, A. E.
    Dima, S.
    Popescu, I.
    Lyden, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S1371 - S1371
  • [33] Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer
    Thanikachalam, Kannan
    Damarla, Vijay
    Seixas, Trevor
    Dobrosotskaya, Irina
    Wollner, Ira
    Kwon, David
    Winters, Kenneth
    Raoufi, Mohammad
    Li, Jia
    Siddiqui, Farzan
    Khan, Gazala
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (06): : 435 - 441
  • [34] Outcomes of a clinical pathway for borderline resectable pancreatic cancer.
    Rashid, Omar Maen
    Pimiento, Jose Mario
    Springett, Gregory M.
    Malafa, Mokenge Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [35] Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer
    Heinemann, V.
    Haas, M.
    Boeck, S.
    ANNALS OF ONCOLOGY, 2013, 24 (10) : 2484 - 2492
  • [36] Multimodality standard of care treatment of resectable and borderline resectable pancreatic cancer
    Neoptolemos, John P.
    Ghaneh, Paula
    Hackert, Thilo
    HEPATOBILIARY SURGERY AND NUTRITION, 2021, 10 (05) : 714 - 716
  • [37] Current Value of Perioperative Therapies for Resectable or Borderline Resectable Pancreatic Cancer
    Murakami, Yuki
    Sakamoto, Teruhisa
    Hanaki, Takehiko
    Tokuyasu, Naruo
    Fujiwara, Yoshiyuki
    YONAGO ACTA MEDICA, 2023, 66 (02) : 202 - 207
  • [38] Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
    Versteijne, Eva
    de Hingh, Ignace H. J. T.
    Homs, Marjolein Y. V.
    Intven, Martijn P. W.
    Klaase, Joost M.
    van Santvoort, Hjalmar C.
    de Vos-Geelen, Judith
    Wilmink, Johanna W.
    van Tienhoven, Geertjan
    FRONTIERS IN ONCOLOGY, 2022, 11
  • [39] Improving outcomes in patients with resectable pancreatic cancer
    Roberts, K. J.
    BRITISH JOURNAL OF SURGERY, 2017, 104 (11) : 1421 - 1423
  • [40] Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma
    Coveler, Andrew L.
    Pillarisetty, Venu G.
    Koh, Wui-Jin
    Zhen, David B.
    Park, James O.
    King, Gentry G.
    Sham, Jonathan G.
    Hannan, Lindsay M.
    Mann, Gary N.
    Baker, Kelsey K.
    Redman, Mary W.
    Swanson, Paul E.
    Chiorean, E. Gabriela
    Whiting, Sam H.
    PANCREAS, 2023, 52 (05) : E282 - E287